Clinical Trial Update: The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating sildenafil citrate in combination with intravenous epoprostenol for pulmonary hypertension has completed with results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Hypertension

Drugs mentioned

• Sildenafil citrate (Sildenafil citrate)
• intravenous epoprostenol (epoprostenol)

Snippet

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Conditions: Pulmonary Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2011-01-12